Heartburn is the main symptom of gastroesophageal reflux disease (GERD). It is experienced by up to 40% of the general population each year, and it is the basis for initiating medical treatment in many patients. Erosive oesophagitis is also a common complication of GERD, being experienced by up to 60% of patients with the disease. GERD symptoms as well as erosive oesophagitis are routinely treated with proton pump inhibitors (PPI). Esomeprazole is a new released PPI. It has been developed as S-isomer of omeprazole, demonstrating pharmaceutical and clinical benefits beyond those seen with the racemic parent compound. This article reviews the most recent published studies to assess the performance of esomeprazole in patients with GERD symptoms and erosive oesophagitis and its cost-effective.
Vaira D., Gatta L., Ricci C., Tampieri A., Casalicchio E., Miglioli M. (2003). Esophagitis and gastroesophageal reflux. INTERNISTA, 11(4), 228-232.
Esophagitis and gastroesophageal reflux
Vaira D.;Gatta L.;Ricci C.;Casalicchio E.;
2003
Abstract
Heartburn is the main symptom of gastroesophageal reflux disease (GERD). It is experienced by up to 40% of the general population each year, and it is the basis for initiating medical treatment in many patients. Erosive oesophagitis is also a common complication of GERD, being experienced by up to 60% of patients with the disease. GERD symptoms as well as erosive oesophagitis are routinely treated with proton pump inhibitors (PPI). Esomeprazole is a new released PPI. It has been developed as S-isomer of omeprazole, demonstrating pharmaceutical and clinical benefits beyond those seen with the racemic parent compound. This article reviews the most recent published studies to assess the performance of esomeprazole in patients with GERD symptoms and erosive oesophagitis and its cost-effective.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
